Skip to main content

Table 3 Association of MTHFR-rs1801133, rs1801131, ERCC2-rs1799793 and rs13181 SNPs with age at diagnosis, family history, ER status, PR status and tumor size of breast cancer patients

From: Significant association between ERCC2 and MTHR polymorphisms and breast cancer susceptibility in Moroccan population: genotype and haplotype analysis in a case-control study

Variable

Model

MTHFR

rs1801133

Genotype

OR (95% CI)a

p b

MTHFR

rs1801131

Genotype

OR (95% CI)

p

ERCC2

rs1799793

Genotype

OR (95% CI)

p

ERCC2

rs13181

Genotype

OR (95% CI)

p

Age

(Years)

(> 40 /≤40)

 

C/C (54/19)c

1

 

A/A (53/30)

1

 

G/G (46/30)

1

 

A/A (53/27)

1

 

He

T/C (27/27)

2.84 (1.35–6.00)

0.006

C/A (34/25)

1.30 (0.66–2.57)

0.45

G/A (35/15)

0.66 (0.31–1.40)

0.28

C/A (27/23)

1.67 (0.81–3.45)

0.16

Ho

T/T (14/10)

2.03 (0.77–5.33)

0.15

C/C (8/1)

0.47 (0.16–1.36)

0.16

A/A (14/11)

1.20 (0.48–3.00)

0.69

C/C (15/6)

0.79 (0.27–2.25)

0.37

D

C/C (54/19)

1

 

A/A (53/30)

1

 

G/G (46/30)

1

 

A/A (53/27)

1

 
 

T/C-T/T (41/37)

2.56 (1.29–5.09)

0.006

C/A-C/C (42/26)

1.09 (0.56–2.12)

0.79

G/A-A/A (49/26)

0.81 (0.42–1.58)

0.54

C/A-C/C (42/29)

1.36 (0.70–2.63)

0.37

R

C/C-T/C (81/46)

1

 

A/A-C/A (87/55)

1

 

G/G-G/A (81/45)

1

 

A/A-C/A (80/50)

1

 
 

T/T (14/10)

1.26 (0.52–3.06)

0.61

C/C (8/1)

0.20 (0.02–1.62)

0.07

A/A (14/11)

1.41 (0.59–3.37)

0.44

C/C (15/6)

0.64 (0.23–1.76)

0.38

OD

C/C-T/T (68/29)

1

 

A/A-C/C (61/31)

1

 

G/G-A/A (60/41)

1

 

A/A-C/C (68/33)

1

 
 

T/C (27/27)

2.34 (1.18–4.67)

0.015

C/A (34/25)

1.45 (0.74–2.84)

0.28

G/A (35/15)

0.63 (0.30–1.29)

0.2

C/A (27/23)

1.76 (0.88–3.52)

0.11

A

–

1.62 (1.03–2.55)

0.036

–

0.89 (0.51–1.53)

0.67

–

1.00 (0.64–1.55)

0.98

–

1.05 (0.66–1.66)

0.84

Family history

(Sporadic/Familial)

 

C/C (51/22)

1

 

A/A (41/42)

1

 

G/G (39/37)

1

 

A/A (40/40)

1

 

He

T/C (18/36)

4.64 (2.18–9.86)

6.8.10 −5

C/A (28/31)

1.08 (0.55–2.11)

0.82

G/A (29/21)

0.76 (0.37–1.57)

0.46

C/A (28/22)

0.79 (0.39–1.60)

0.5

Ho

T/T (8/16)

4.64 (1.73–12.42)

0.002

C/C (8/1)

0.12 (0.01–1.02)

0.05

A/A (9/16)

1.87 (0.74–4.76)

0.18

C/C (9/12)

1.33 (0.51–3.51)

0.56

D

C/C (51/22)

1

 

A/A (41/42)

1

 

G/G (39/37)

1

 

A/A (40/40)

1

 
 

T/C-T/T (26/52)

4.64 (2.33–9.21)

< 10 −4

C/A-C/C (36/32)

0.87 (0.46–1.65)

0.66

G/A-A/A (38/37)

1.03 (0.54–1.94)

0.94

C/A-C/C (37/34)

0.92 (0.48–1.74)

0.8

R

C/C-T/C (69/58)

1

 

A/A-C/A (69/73)

1

 

G/G-G/A (68/58)

1

 

A/A-C/A (68/62)

1

 
 

T/T (8/16)

2.38 (0.95–5.96)

0.057

C/C (8/1)

0.12 (0.01–0.97)

0.01

A/A (9/16)

2.08 (0.86–5.07)

0.1

C/C (9/12)

1.46 (0.58–3.71)

0.42

OD

C/C-T/T (59/38)

1

 

A/A-C/C (49/43)

1

 

G/G-A/A (48/53)

1

 

A/A-C/C (49/52)

1

 
 

T/C (18/36)

3.11 (1.55–6.24)

0.001

C/A (28/31)

1.26 (0.66–2.43)

0.49

G/A (29/21)

0.66 (0.33–1.30)

0.22

C/A (28/22)

0.74 (0.37–1.46)

0.39

A

–

2.61 (1.60–4.25)

< 10 −4

–

0.71 (0.42–1.21)

0.2

–

1.21 (0.79–1.86)

0.38

–

1.05 (0.67–1.63)

0.84

ER

Status

(Positive/ Negative)

 

C/C (52/18)

1

 

A/A (62/16)

1

 

G/G (48/22)

1

 

A/A (53/21)

1

 

He

T/C (35/14)

1.16 (0.51–2.62)

0.73

C/A (39/18)

1.79 (0.82–3.92)

0.14

G/A (38/12)

0.69 (0.30–1.57)

0.37

C/A (36/12)

0.84 (0.37–1.92)

0.68

Ho

T/T (20/4)

0.58 (0.17–1.92)

0.37

C/C (6/2)

1.29 (0.24–7.01)

0.8

A/A (21/2)

0.21 (0.04–0.96)

0.045

C/C (18/3)

0.42 (0.11–1.58)

0.2

D

C/C (52/18)

1

 

A/A (62/16)

1

 

G/G (48/22)

1

 

A/A (53/21)

1

 
 

T/C-T/T (55/18)

0.95 (0.44–2.01)

0.88

C/A-C/C (45/20)

1.72 (0.80–3.69)

0.16

G/A-A/A (59/14)

0.52 (0.24–1.12)

0.091

C/A-C/C (54/15)

0.70 (0.33–1.50)

0.36

R

C/C-T/C (87/32)

1

 

A/A-C/A (101/34)

1

 

G/G-G/A (86/34)

1

 

A/A-C/A (89/33)

1

 
 

T/T (20/4)

0.54 (0.17–1.71)

0.28

C/C (6/2)

0.99 (0.19–5.14)

0.99

A/A (21/2)

0.24 (0.05–1.08)

0.03

C/C (18/3)

0.45 (0.12–1.63)

0.19

OD

C/C-T/T (72/22)

1

 

A/A-C/C (68/18)

1

 

G/G-A/A (69/24)

1

 

A/A-C/C (71/24)

1

 
 

T/C (35/14)

1.31 (0.60–2.86)

0.5

C/A (39/18)

1.74 (0.81–3.74)

0.15

G/A (38/12)

0.91 (0.41–2.02)

0.81

C/A (36/12)

0.99 (0.44–2.20)

0.97

A

–

0.85 (0.50–1.42)

0.53

–

1.43 (0.78–2.65)

0.25

–

0.54 (0.30–0.96)

0.028

–

0.71 (0.41–1.23)

0.21

PR

Status

(Positive/Negative)

 

C/C (46/23)

1

 

A/A (49/25)

1

 

G/G (40/27)

1

 

A/A (48/23)

1

 

He

T/C (27/18)

1.33 (0.61–2.90)

0.47

C/A (36/19)

1.03 (0.50–2.16)

0.93

G/A (30/17)

0.84 (0.39–1.81)

0.66

C/A (25/20)

1.67 (0.77–3.61)

0.19

Ho

T/T (16/7)

0.88 (0.32–2.43)

0.8

C/C (4/4)

1.96 (0.45–8.50)

0.4

A/A (19/4)

0.31 (0.09–1.02)

0.05

C/C (16/5)

0.81 (0.46–1.41)

0.45

D

C/C (46/23)

1

 

A/A (49/25)

1

 

G/G (40/27)

1

 

A/A (48/23)

1

 
 

T/C-T/T (43/25)

1.16 (0.58–2.35)

0.67

C/A-C/C (40/23)

1.13 (0.56–2.28)

0.74

G/A-A/A (49/21)

0.63 (0.31–1.29)

0.21

C/A-C/C (41/25)

1.27 (0.63–2.57)

0.5

R

C/C-T/C (73/41)

1

 

A/A-C/A (85/44)

1

 

G/G-G/A (70/44)

1

 

A/A-C/A (73/43)

1

 
 

T/T (16/7)

0.78 (0.30–2.05)

0.61

C/C (4/4)

1.93 (0.46–8.10)

0.37

A/A (19/4)

0.33 (0.11–1.05)

0.04

C/C (16/5)

0.53 (0.18–1.55)

0.23

OD

C/C-T/T (62/30)

1

 

A/A-C/C (53/29)

1

 

G/G-A/A (59/31)

1

 

A/A-C/C (64/28)

1

 
 

T/C (27/18)

1.38 (0.66–2.88)

0.4

C/A (36/19)

0.96 (0.47–1.98)

0.92

G/A (30/17)

1.08 (0.52–2.25)

0.84

C/A (25/20)

1.83 (0.88–3.82)

0.11

A

–

1.01 (0.63–1.61)

0.98

–

1.20 (0.68–2.14)

0.53

–

0.63 (0.38–1.04)

0.06

–

0.97 (0.60–1.57)

0.91

Tumor

size

(T1 / ≥ T3)

 

C/C (10/14)

1

 

A/A (10/14)

1

 

G/G (12/16)

1

 

A/A (15/11)

1

 

He

T/C (11/10)

0.65 (0.20–2.11)

0.47

C/A (13/12)

0.66 (0.21–2.04)

0.47

G/A (8/8)

0.75 (0.22–2.57)

0.65

C/A (5/15)

4.09 (1.14–14.7)

0.03

Ho

T/T (3/4)

0.95 (0.17–5.23)

0.95

C/C (1/2)

1.43 (0.11–18.0)

0.78

A/A (4/4)

0.75 (0.16–3.62)

0.72

C/C (4/2)

0.68 (0.11–4.41)

0.68

D

C/C (10/14)

1

 

A/A (10/14)

1

 

G/G (12/16)

1

 

A/A (15/11)

1

 
 

T/C-T/T (14/14)

0.71 (0.24–2.14)

0.55

C/A-C/C (14/14)

0.71 (0.24–2.14)

0.55

G/A-A/A (12/12)

0.75 (0.25–2.24)

0.61

C/A-C/C (9/17)

2.58 (0.84–7.91)

0.09

R

C/C-T/C (21/24)

1

 

A/A-C/A (23/26)

1

 

G/G-G/A (20/24)

1

 

A/A-C/A (20/26)

1

 
 

T/T (3/4)

1.17 (0.23–5.82)

0.85

C/C (1/2)

1.77 (0.15–20.8)

0.64

A/A (4/4)

0.83 (0.18–3.76)

0.81

C/C (4/2)

0.38 (0.06–2.31)

0.28

OD

C/C-T/T (13/18)

1

 

A/A-C/C (11/16)

1

 

G/G-A/A (16/20)

1

 

A/A-C/C (19/13)

1

 
 

T/C (11/10)

0.66 (0.22–2.00)

0.46

C/A (13/12)

0.63 (0.21–1.9)

0.42

G/A (8/8)

0.80 (0.25–2.6)

0.71

C/A (5/15)

4.38 (1.28–15.1)

0.01

A

–

0.87 (0.40–1.91)

0.74

–

0.86 (0.34–2.15)

0.75

–

0.84 (0.40–1.76)

0.64

–

1.35 (0.60–3.03)

0.47

  1. aOR (Odds ratio) and 95% CI (confidence interval)
  2. bbold values are statistically significant (p < 0.05)
  3. cnumber of individuals, ER estrogen receptor, PR progesterone receptor, He Heterozygote, Ho Homozygote, D Dominant, R Recessive, OD Overdominant, A Log-additive
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us